Evolution of the Average Target: Exelixis, Inc.

Evolution of the Target Price: Exelixis, Inc.

Changes in Analyst Recommendations: Exelixis, Inc.

9a9cc776780b4c.LU9eboCvx5ezqttaYkfN4YV1o0gLI23o5qPUlN7tRkk.QBkRN8zupNvj-4spMBieo8c28w1URx6vsfXsp5SuMxFMN2cMzfC0-_nZmg~108bfe8f1ebf8e36677173fda64fea16
07-23 Analyst recommendations: Duke Energy, JPMorgan Chase, M&T Bank, Super Micro, Texas Instruments… Zonebourse
07-13 Analyst recommendations: Biogen, Deckers Outdoor, Fortinet, Marathon Petroleum, UnitedHealth… Zonebourse
07-07 RBC Capital Adjusts Exelixis Price Target to $46 From $43, Maintains Sector Perform Rating MT
07-02 Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says MT
07-02 UBS Adjusts Price Target on Exelixis to $52 From $43, Maintains Neutral Rating MT
07-02 Analyst recommendations: Adobe, AA, Nike, Exelixis… Zonebourse
05-06 Exelixis Seen Trading Steady on Modest Drug Growth, RBC Says MT
03-02 RBC Lowers Price Target on Exelixis to $43 From $46, Keeps Sector Perform Rating MT
02-11 RBC Raises Price Target on Exelixis to $46 From $45, Keeps Sector Perform Rating MT
02-02 Morgan Stanley Lifts Price Target on Exelixis to $49 From $48, Keeps Overweight Rating MT
01-14 Truist Securities Adjusts Price Target on Exelixis to $51 From $49, Maintains Buy Rating MT
01-08 Exelixis Shares Fall After Downgrade From Morgan Stanley MT
01-08 Morgan Stanley Downgrades Exelixis to Equalweight, Price Target is $48 MT
01-05 Exelixis Faces Limited High-Impact Catalysts, BofA Says MT
01-05 BofA Securities Downgrades Exelixis to Underperform From Neutral, Adjusts Price Target to $41 From $43 MT
11-06 UBS Adjusts Price Target on Exelixis to $40 From $35, Maintains Neutral Rating MT
11-05 Morgan Stanley Lifts Price Target on Exelixis to $45 From $44, Keeps Overweight Rating MT
11-03 Exelixis Shares Fall After Guggenheim Downgrade MT
11-03 Guggenheim Downgrades Exelixis to Neutral From Buy MT
25-10-21 Exelixis Shares Rise After Leerink Partners Upgrade MT
25-10-21 Leerink Partners Upgrades Exelixis to Outperform From Market Perform, Adjusts Price Target to $48 From $38 MT
25-10-18 Exelixis, Inc. Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating Cabozantinib in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025 CI
25-07-30 UBS Adjusts Price Target on Exelixis to $38 From $43, Maintains Neutral Rating MT
25-07-29 Analyst recommendations: Blackstone, Airbnb, Amphenol, Cadence Design Systems, Ameriprise Financial... Zonebourse
25-07-29 RBC Lowers Price Target on Exelixis to $45 From $50, Keeps Sector Perform Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
-6.92%
+11.79%
+23.73%
+22.76%
+25.05%
+10.75%
+20.83%
+45.83%
+3.91%
+20.97%
Average +17.87%
Weighted average by Cap. +18.92%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
58.39USD
Average target price
53.93USD
Spread / Average Target
-7.63%
High Price Target
66.00USD
Spread / Highest target
+13.03%
Low Price Target
41.00USD
Spread / Lowest Target
-29.78%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. EXEL Stock
  4. Consensus Exelixis, Inc.